JP2976381B2 - 細胞間粘着分子およびその結合性リガンド - Google Patents

Info

Publication number

JP2976381B2

JP2976381B2 JP1510885A JP51088589A JP2976381B2 JP 2976381 B2 JP2976381 B2 JP 2976381B2 JP 1510885 A JP1510885 A JP 1510885A JP 51088589 A JP51088589 A JP 51088589A JP 2976381 B2 JP2976381 B2 JP 2976381B2

Authority

JP

Japan

Prior art keywords

icam

cells

lfa

binding

cell

Prior art date

1988-09-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 title claims description 139
• 239000003446 ligand Substances 0.000 title description 35
• 102000016289 Cell Adhesion Molecules Human genes 0.000 title description 6
• 108010067225 Cell Adhesion Molecules Proteins 0.000 title description 6
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 541
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 160
• 239000012634 fragment Substances 0.000 claims description 43
• 206010061218 Inflammation Diseases 0.000 claims description 42
• 230000004054 inflammatory process Effects 0.000 claims description 42
• 210000004698 lymphocyte Anatomy 0.000 claims description 41
• 108060003951 Immunoglobulin Proteins 0.000 claims description 37
• 102000018358 immunoglobulin Human genes 0.000 claims description 37
• 230000004044 response Effects 0.000 claims description 29
• 230000001419 dependent effect Effects 0.000 claims description 28
• 125000000539 amino acid group Chemical group 0.000 claims description 23
• 239000005557 antagonist Substances 0.000 claims description 23
• 239000003053 toxin Substances 0.000 claims description 20
• 231100000765 toxin Toxicity 0.000 claims description 20
• 230000002401 inhibitory effect Effects 0.000 claims description 19
• 239000000126 substance Substances 0.000 claims description 15
• 210000004881 tumor cell Anatomy 0.000 claims description 14
• 230000001086 cytosolic effect Effects 0.000 claims description 12
• 239000003814 drug Substances 0.000 claims description 12
• 230000035886 specific defense system Effects 0.000 claims description 12
• 229930105110 Cyclosporin A Natural products 0.000 claims description 11
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 11
• 108010036949 Cyclosporine Proteins 0.000 claims description 11
• 229960001265 ciclosporin Drugs 0.000 claims description 11
• 102100025390 Integrin beta-2 Human genes 0.000 claims description 9
• 239000013598 vector Substances 0.000 claims description 9
• 239000003018 immunosuppressive agent Substances 0.000 claims description 8
• 229940079593 drug Drugs 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 230000035781 nonspecific defense system Effects 0.000 claims description 7
• 239000008194 pharmaceutical composition Substances 0.000 claims description 7
• 230000012010 growth Effects 0.000 claims description 6
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
• 238000012546 transfer Methods 0.000 claims description 5
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 4
• 108020004511 Recombinant DNA Proteins 0.000 claims description 4
• 230000009257 reactivity Effects 0.000 claims description 4
• 102000053602 DNA Human genes 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 3
• 229960003957 dexamethasone Drugs 0.000 claims description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
• 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 3
• 230000001900 immune effect Effects 0.000 claims description 3
• 230000001861 immunosuppressant effect Effects 0.000 claims description 3
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 17
• 244000005700 microbiome Species 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 230000004962 physiological condition Effects 0.000 claims 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 506
• 210000004027 cell Anatomy 0.000 description 359
• 238000000034 method Methods 0.000 description 95
• 230000014509 gene expression Effects 0.000 description 76
• 230000002776 aggregation Effects 0.000 description 71
• 238000004220 aggregation Methods 0.000 description 71
• 210000002510 keratinocyte Anatomy 0.000 description 53
• 108090000623 proteins and genes Proteins 0.000 description 53
• 230000000694 effects Effects 0.000 description 44
• 239000002299 complementary DNA Substances 0.000 description 42
• 238000012360 testing method Methods 0.000 description 40
• 108091034117 Oligonucleotide Proteins 0.000 description 38
• 210000001519 tissue Anatomy 0.000 description 37
• 210000002889 endothelial cell Anatomy 0.000 description 36
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 36
• 238000011282 treatment Methods 0.000 description 36
• 239000000427 antigen Substances 0.000 description 33
• 108091007433 antigens Proteins 0.000 description 33
• 102000036639 antigens Human genes 0.000 description 33
• 108020004414 DNA Proteins 0.000 description 32
• 210000004408 hybridoma Anatomy 0.000 description 31
• 238000003556 assay Methods 0.000 description 28
• 210000000265 leukocyte Anatomy 0.000 description 24
• 239000002609 medium Substances 0.000 description 24
• 102000004169 proteins and genes Human genes 0.000 description 24
• 239000012528 membrane Substances 0.000 description 23
• 108090000765 processed proteins & peptides Proteins 0.000 description 23
• 235000018102 proteins Nutrition 0.000 description 23
• 238000010186 staining Methods 0.000 description 23
• 210000005087 mononuclear cell Anatomy 0.000 description 22
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 21
• 102000000589 Interleukin-1 Human genes 0.000 description 20
• 108010002352 Interleukin-1 Proteins 0.000 description 20
• 239000013604 expression vector Substances 0.000 description 20
• 238000002360 preparation method Methods 0.000 description 20
• 239000000523 sample Substances 0.000 description 20
• 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 description 19
• 241001465754 Metazoa Species 0.000 description 19
• 229920002684 Sepharose Polymers 0.000 description 19
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 19
• 239000000203 mixture Substances 0.000 description 19
• 210000000056 organ Anatomy 0.000 description 19
• 108700012359 toxins Proteins 0.000 description 19
• 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 description 18
• 102100021831 Myelin-associated glycoprotein Human genes 0.000 description 18
• 125000003275 alpha amino acid group Chemical group 0.000 description 18
• 238000001574 biopsy Methods 0.000 description 18
• 230000003993 interaction Effects 0.000 description 18
• 230000006870 function Effects 0.000 description 17
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
• 230000001225 therapeutic effect Effects 0.000 description 17
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• 239000003599 detergent Substances 0.000 description 16
• 102000006354 HLA-DR Antigens Human genes 0.000 description 15
• 108010058597 HLA-DR Antigens Proteins 0.000 description 15
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 15
• 102000008070 Interferon-gamma Human genes 0.000 description 15
• 108010074328 Interferon-gamma Proteins 0.000 description 15
• 229920004890 Triton X-100 Polymers 0.000 description 15
• 239000013504 Triton X-100 Substances 0.000 description 15
• 235000001014 amino acid Nutrition 0.000 description 15
• 230000015572 biosynthetic process Effects 0.000 description 15
• 239000012894 fetal calf serum Substances 0.000 description 15
• 239000003795 chemical substances by application Substances 0.000 description 14
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
• 229940044627 gamma-interferon Drugs 0.000 description 14
• 239000011159 matrix material Substances 0.000 description 14
• 210000003491 skin Anatomy 0.000 description 14
• 239000006228 supernatant Substances 0.000 description 14
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 13
• 210000001744 T-lymphocyte Anatomy 0.000 description 13
• 229940024606 amino acid Drugs 0.000 description 13
• 150000001413 amino acids Chemical class 0.000 description 13
• 238000010367 cloning Methods 0.000 description 13
• 230000002950 deficient Effects 0.000 description 13
• 239000002644 phorbol ester Substances 0.000 description 13
• 229920003023 plastic Polymers 0.000 description 13
• 239000004033 plastic Substances 0.000 description 13
• 108010062580 Concanavalin A Proteins 0.000 description 12
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 230000021164 cell adhesion Effects 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 210000002950 fibroblast Anatomy 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 241000699670 Mus sp. Species 0.000 description 11
• 229940121363 anti-inflammatory agent Drugs 0.000 description 11
• 239000002260 anti-inflammatory agent Substances 0.000 description 11
• 238000012217 deletion Methods 0.000 description 11
• 230000037430 deletion Effects 0.000 description 11
• 239000002158 endotoxin Substances 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 108010044426 integrins Proteins 0.000 description 11
• 102000006495 integrins Human genes 0.000 description 11
• 230000003902 lesion Effects 0.000 description 11
• 239000002773 nucleotide Substances 0.000 description 11
• 125000003729 nucleotide group Chemical group 0.000 description 11
• 210000004989 spleen cell Anatomy 0.000 description 11
• 231100000331 toxic Toxicity 0.000 description 11
• 230000002588 toxic effect Effects 0.000 description 11
• 108010047620 Phytohemagglutinins Proteins 0.000 description 10
• 239000012980 RPMI-1640 medium Substances 0.000 description 10
• 108090000631 Trypsin Proteins 0.000 description 10
• 102000004142 Trypsin Human genes 0.000 description 10
• 230000001154 acute effect Effects 0.000 description 10
• 230000000172 allergic effect Effects 0.000 description 10
• 208000010668 atopic eczema Diseases 0.000 description 10
• 239000000872 buffer Substances 0.000 description 10
• 230000000295 complement effect Effects 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• 230000002757 inflammatory effect Effects 0.000 description 10
• 230000001885 phytohemagglutinin Effects 0.000 description 10
• 238000002054 transplantation Methods 0.000 description 10
• 239000012588 trypsin Substances 0.000 description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• -1 for example Proteins 0.000 description 9
• 238000009396 hybridization Methods 0.000 description 9
• 239000006166 lysate Substances 0.000 description 9
• 230000001404 mediated effect Effects 0.000 description 9
• 239000003226 mitogen Substances 0.000 description 9
• 102000004196 processed proteins & peptides Human genes 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 210000002966 serum Anatomy 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• 101000936738 Coturnix japonica Astacin-like metalloendopeptidase Proteins 0.000 description 8
• 102000003886 Glycoproteins Human genes 0.000 description 8
• 108090000288 Glycoproteins Proteins 0.000 description 8
• 101000794562 Naegleria gruberi Calmodulin, flagellar Proteins 0.000 description 8
• 102000007079 Peptide Fragments Human genes 0.000 description 8
• 108010033276 Peptide Fragments Proteins 0.000 description 8
• 239000007983 Tris buffer Substances 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 230000028993 immune response Effects 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 210000003734 kidney Anatomy 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 230000037311 normal skin Effects 0.000 description 8
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 210000000952 spleen Anatomy 0.000 description 8
• 238000006467 substitution reaction Methods 0.000 description 8
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
• 108020004705 Codon Proteins 0.000 description 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
• 206010025323 Lymphomas Diseases 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 229940109239 creatinine Drugs 0.000 description 7
• 201000010099 disease Diseases 0.000 description 7
• 230000013595 glycosylation Effects 0.000 description 7
• 238000006206 glycosylation reaction Methods 0.000 description 7
• 210000003714 granulocyte Anatomy 0.000 description 7
• 230000003053 immunization Effects 0.000 description 7
• 238000001114 immunoprecipitation Methods 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 230000008595 infiltration Effects 0.000 description 7
• 238000001764 infiltration Methods 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 7
• 210000001165 lymph node Anatomy 0.000 description 7
• 210000002540 macrophage Anatomy 0.000 description 7
• 238000012216 screening Methods 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 229960000814 tetanus toxoid Drugs 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• 102000002110 C2 domains Human genes 0.000 description 6
• 108050009459 C2 domains Proteins 0.000 description 6
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
• 229930182566 Gentamicin Natural products 0.000 description 6
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• 201000004681 Psoriasis Diseases 0.000 description 6
• 108091034057 RNA (poly(A)) Proteins 0.000 description 6
• 206010052779 Transplant rejections Diseases 0.000 description 6
• 238000007818 agglutination assay Methods 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 230000017455 cell-cell adhesion Effects 0.000 description 6
• 238000005119 centrifugation Methods 0.000 description 6
• 239000012228 culture supernatant Substances 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 229960002518 gentamicin Drugs 0.000 description 6
• 230000028709 inflammatory response Effects 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• 201000000050 myeloid neoplasm Diseases 0.000 description 6
• HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 6
• 210000002741 palatine tonsil Anatomy 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 238000007390 skin biopsy Methods 0.000 description 6
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
• 239000000758 substrate Substances 0.000 description 6
• 210000003462 vein Anatomy 0.000 description 6
• 241000282693 Cercopithecidae Species 0.000 description 5
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 5
• 102000018697 Membrane Proteins Human genes 0.000 description 5
• 108010052285 Membrane Proteins Proteins 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 102100040247 Tumor necrosis factor Human genes 0.000 description 5
• 238000001042 affinity chromatography Methods 0.000 description 5
• 210000004102 animal cell Anatomy 0.000 description 5
• 150000001768 cations Chemical class 0.000 description 5
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 238000001962 electrophoresis Methods 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 210000005260 human cell Anatomy 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 239000012535 impurity Substances 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 239000012139 lysis buffer Substances 0.000 description 5
• 239000011777 magnesium Substances 0.000 description 5
• 229910001425 magnesium ion Inorganic materials 0.000 description 5
• 230000009401 metastasis Effects 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 238000000159 protein binding assay Methods 0.000 description 5
• 208000017520 skin disease Diseases 0.000 description 5
• 231100000444 skin lesion Toxicity 0.000 description 5
• 206010040882 skin lesion Diseases 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 108010039627 Aprotinin Proteins 0.000 description 4
• 208000002109 Argyria Diseases 0.000 description 4
• 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• 108091026890 Coding region Proteins 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 4
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 4
• 230000004988 N-glycosylation Effects 0.000 description 4
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
• 239000004098 Tetracycline Substances 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 230000000735 allogeneic effect Effects 0.000 description 4
• 229960000723 ampicillin Drugs 0.000 description 4
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
• 230000000181 anti-adherent effect Effects 0.000 description 4
• 229960004405 aprotinin Drugs 0.000 description 4
• 239000000823 artificial membrane Substances 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 239000012148 binding buffer Substances 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 229910001424 calcium ion Inorganic materials 0.000 description 4
• 239000013592 cell lysate Substances 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 208000037976 chronic inflammation Diseases 0.000 description 4
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 239000000032 diagnostic agent Substances 0.000 description 4
• 229940039227 diagnostic agent Drugs 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 239000010408 film Substances 0.000 description 4
• 239000011521 glass Substances 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
• 239000000833 heterodimer Substances 0.000 description 4
• 239000012133 immunoprecipitate Substances 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 201000011486 lichen planus Diseases 0.000 description 4
• 239000002751 oligonucleotide probe Substances 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000001185 psoriatic effect Effects 0.000 description 4
• 230000000717 retained effect Effects 0.000 description 4
• 238000007423 screening assay Methods 0.000 description 4
• 239000002356 single layer Substances 0.000 description 4
• 210000001626 skin fibroblast Anatomy 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 229960002180 tetracycline Drugs 0.000 description 4
• 229930101283 tetracycline Natural products 0.000 description 4
• 235000019364 tetracycline Nutrition 0.000 description 4
• 150000003522 tetracyclines Chemical class 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 230000005951 type IV hypersensitivity Effects 0.000 description 4
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 206010002091 Anaesthesia Diseases 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
• 108010084313 CD58 Antigens Proteins 0.000 description 3
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 102100031780 Endonuclease Human genes 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 108010067306 Fibronectins Proteins 0.000 description 3
• 102000016359 Fibronectins Human genes 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 3
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 3
• 108091092195 Intron Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 102100023058 NHP2-like protein 1 Human genes 0.000 description 3
• 101710177157 NHP2-like protein 1 Proteins 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 239000012979 RPMI medium Substances 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 238000002105 Southern blotting Methods 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000002730 additional effect Effects 0.000 description 3
• 230000037005 anaesthesia Effects 0.000 description 3
• 239000003911 antiadherent Substances 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 239000003855 balanced salt solution Substances 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 238000011260 co-administration Methods 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 238000000502 dialysis Methods 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 229930182470 glycoside Natural products 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 229940125721 immunosuppressive agent Drugs 0.000 description 3
• 230000008611 intercellular interaction Effects 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 230000003907 kidney function Effects 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 3
• 229940046781 other immunosuppressants in atc Drugs 0.000 description 3
• 230000035515 penetration Effects 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 102000013415 peroxidase activity proteins Human genes 0.000 description 3
• 108040007629 peroxidase activity proteins Proteins 0.000 description 3
• 229920002401 polyacrylamide Polymers 0.000 description 3
• 229920000136 polysorbate Polymers 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 210000003752 saphenous vein Anatomy 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
• CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 229940104230 thymidine Drugs 0.000 description 3
• 230000014616 translation Effects 0.000 description 3
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 3
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 3
• 210000003556 vascular endothelial cell Anatomy 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 229910000166 zirconium phosphate Inorganic materials 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 2
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 2
• 108700010070 Codon Usage Proteins 0.000 description 2
• 108010078015 Complement C3b Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 206010012434 Dermatitis allergic Diseases 0.000 description 2
• 108010042407 Endonucleases Proteins 0.000 description 2
• 208000010201 Exanthema Diseases 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 102000028180 Glycophorins Human genes 0.000 description 2
• 108091005250 Glycophorins Proteins 0.000 description 2
• 102000009485 HLA-D Antigens Human genes 0.000 description 2
• 108010048896 HLA-D Antigens Proteins 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
• 102000003777 Interleukin-1 beta Human genes 0.000 description 2
• 108090000193 Interleukin-1 beta Proteins 0.000 description 2
• 108010082786 Interleukin-1alpha Proteins 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 108010093965 Polymyxin B Proteins 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 102100037204 Sal-like protein 1 Human genes 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 239000004809 Teflon Substances 0.000 description 2
• 229920006362 Teflon® Polymers 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 229940124599 anti-inflammatory drug Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 150000001540 azides Chemical class 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 238000003352 cell adhesion assay Methods 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000008614 cellular interaction Effects 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000002500 effect on skin Effects 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 2
• 239000005038 ethylene vinyl acetate Substances 0.000 description 2
• 201000005884 exanthem Diseases 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 210000001280 germinal center Anatomy 0.000 description 2
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 239000010903 husk Substances 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 238000010185 immunofluorescence analysis Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000005732 intercellular adhesion Effects 0.000 description 2
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 208000017830 lymphoblastoma Diseases 0.000 description 2
• 210000005004 lymphoid follicle Anatomy 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• 239000003094 microcapsule Substances 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 238000013059 nephrectomy Methods 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
• 210000001986 peyer's patch Anatomy 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 150000004633 phorbol derivatives Chemical class 0.000 description 2
• 239000013600 plasmid vector Substances 0.000 description 2
• 231100000614 poison Toxicity 0.000 description 2
• 230000007096 poisonous effect Effects 0.000 description 2
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920000024 polymyxin B Polymers 0.000 description 2
• 229960005266 polymyxin b Drugs 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 230000009696 proliferative response Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 210000001243 pseudopodia Anatomy 0.000 description 2
• 238000012207 quantitative assay Methods 0.000 description 2
• 206010037844 rash Diseases 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 238000005063 solubilization Methods 0.000 description 2
• 230000007928 solubilization Effects 0.000 description 2
• 230000003381 solubilizing effect Effects 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 239000010409 thin film Substances 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 210000003606 umbilical vein Anatomy 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
• 101150007523 32 gene Proteins 0.000 description 1
• BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
• OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
• 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
• 102100033326 Alpha-1B-glycoprotein Human genes 0.000 description 1
• 101710104910 Alpha-1B-glycoprotein Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 101001011741 Bos taurus Insulin Proteins 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 108091028026 C-DNA Proteins 0.000 description 1
• 101100165918 Caenorhabditis elegans cam-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 208000025985 Central nervous system inflammatory disease Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 208000032862 Clinical Deterioration Diseases 0.000 description 1
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 101710081048 Endonuclease III Proteins 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 241000272184 Falconiformes Species 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
• 108010075704 HLA-A Antigens Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 108091027305 Heteroduplex Proteins 0.000 description 1
• 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
• 101100456320 Homo sapiens NR3C2 gene Proteins 0.000 description 1
• 101000581986 Homo sapiens Neurocan core protein Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 238000012695 Interfacial polymerization Methods 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
• 239000006142 Luria-Bertani Agar Substances 0.000 description 1
• 239000006137 Luria-Bertani broth Substances 0.000 description 1
• 239000004907 Macro-emulsion Substances 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
• 101150114886 NECTIN1 gene Proteins 0.000 description 1
• 241001460678 Napo <wasp> Species 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• 102100023064 Nectin-1 Human genes 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 108050003738 Neural cell adhesion molecule 1 Proteins 0.000 description 1
• 102100030466 Neurocan core protein Human genes 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 102400000745 Potential peptide Human genes 0.000 description 1
• 101800001357 Potential peptide Proteins 0.000 description 1
• 239000004792 Prolene Substances 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010038470 Renal infarct Diseases 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 239000012722 SDS sample buffer Substances 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 208000028990 Skin injury Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 108010031318 Vitronectin Proteins 0.000 description 1
• 102100035140 Vitronectin Human genes 0.000 description 1
• GPKUGWDQUVWHIC-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NNC1=CC=C(C=C1)C1=CC=C(NN)C=C1 GPKUGWDQUVWHIC-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000007801 affinity label Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 230000004520 agglutination Effects 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
• 238000011316 allogeneic transplantation Methods 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 210000003969 blast cell Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
• GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 101150091339 cam-1 gene Proteins 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000008619 cell matrix interaction Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000005354 coacervation Methods 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 150000001945 cysteines Chemical group 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000022811 deglycosylation Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002059 diagnostic imaging Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 239000005546 dideoxynucleotide Substances 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 210000001840 diploid cell Anatomy 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 210000001339 epidermal cell Anatomy 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 210000001102 germinal center b cell Anatomy 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 150000002333 glycines Chemical class 0.000 description 1
• 108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 description 1
• 108010044896 glycyl-arginyl-glycyl-glutamyl-seryl-proline Proteins 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• WPIULSIZRNJJDL-UHFFFAOYSA-N guanidine;isocyanic acid Chemical compound N=C=O.NC(N)=N WPIULSIZRNJJDL-UHFFFAOYSA-N 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000000322 hemodialysis Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 230000001744 histochemical effect Effects 0.000 description 1
• 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• 238000011862 kidney biopsy Methods 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000008384 membrane barrier Effects 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 229940105132 myristate Drugs 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 210000002241 neurite Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 230000001582 osteoblastic effect Effects 0.000 description 1
• 230000001009 osteoporotic effect Effects 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 210000003240 portal vein Anatomy 0.000 description 1
• 230000003334 potential effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• CJBPIZBHRWDBGQ-COSFPPCYSA-N rfa-1 Chemical compound C1([C@H]2N[C@H](CC3(N=C4C=5C6=C7O[C@](C6=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C4N3)C(=O)C=5C(O)=C7C)C)OC)C2)C=2C=CC=CC=2)=CC=CC=C1 CJBPIZBHRWDBGQ-COSFPPCYSA-N 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 108700004121 sarkosyl Proteins 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 210000003786 sclera Anatomy 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 206010040400 serum sickness Diseases 0.000 description 1
• 238000010008 shearing Methods 0.000 description 1
• 239000013605 shuttle vector Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 238000002791 soaking Methods 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 231100000342 urinary toxicity Toxicity 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1